PF614-MPAR

PF614-MPAR is a next-generation, oral opioid analgesic developed to treat severe pain while providing built-in protection against overdose. It is a combination product that delivers oxycodone for pain relief at prescribed doses but incorporates proprietary overdose protection technology. The drug uses Ensysce Biosciences' TAAP and MPAR platforms, which together limit the release of oxycodone if more than the prescribed amount is consumed, effectively "shutting down" opioid release in overdose scenarios. This dual-mechanism approach provides both abuse deterrence and overdose inhibition by co-formulating a trypsin inhibitor with the prodrug system, reducing maximum blood concentrations of oxycodone during attempted overdoses without compromising therapeutic efficacy at normal doses[1][2][3][6][7][8]. Clinical studies have demonstrated dose-dependent overdose protection across the full planned commercial dosage range with no unexpected adverse events reported[1][3][5]. PF614-MPAR has received Breakthrough Therapy designation from the FDA—the first opioid to do so—highlighting its potential as an innovative solution for safer pain management[4][7].

Brand names

PF614-MPARPF-614-MPARPF 614-MPAR

Other names

PF614-MPARPF-614-MPARPF 614-MPAR